Virginia Retirement Systems ET AL bought a new stake in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) during the third quarter, Holdings Channel reports. The fund bought 21,700 shares of the biopharmaceutical company’s stock, valued at approximately $361,000. Virginia Retirement Systems ET AL owned about 0.05% of Vanda Pharmaceuticals as of its most recent filing with the SEC.
A number of other large investors have also bought and sold shares of the company. Bank of Montreal Can acquired a new stake in Vanda Pharmaceuticals during the second quarter valued at $132,000. UBS Asset Management Americas Inc. boosted its stake in Vanda Pharmaceuticals by 10.9% in the second quarter. UBS Asset Management Americas Inc. now owns 16,300 shares of the biopharmaceutical company’s stock valued at $182,000 after buying an additional 1,600 shares during the last quarter. Paloma Partners Management Co acquired a new stake in Vanda Pharmaceuticals during the second quarter valued at $192,000. Jane Street Group LLC acquired a new stake in Vanda Pharmaceuticals during the second quarter valued at $200,000. Finally, TFS Capital LLC acquired a new stake in Vanda Pharmaceuticals during the second quarter valued at $210,000. Hedge funds and other institutional investors own 88.41% of the company’s stock.
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) traded down 0.29% on Friday, hitting $17.30. The stock had a trading volume of 285,022 shares. The company’s market cap is $760.27 million. The company’s 50 day moving average price is $16.07 and its 200-day moving average price is $13.37. Vanda Pharmaceuticals Inc. has a 12-month low of $6.91 and a 12-month high of $18.00.
Vanda Pharmaceuticals (NASDAQ:VNDA) last posted its earnings results on Wednesday, November 2nd. The biopharmaceutical company reported ($0.01) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.13. Vanda Pharmaceuticals had a negative return on equity of 16.13% and a negative net margin of 23.07%. The business earned $38.48 million during the quarter, compared to analyst estimates of $38.05 million. During the same quarter last year, the firm earned ($0.22) earnings per share. The company’s revenue for the quarter was up 35.8% compared to the same quarter last year. Equities research analysts anticipate that Vanda Pharmaceuticals Inc. will post ($0.45) EPS for the current year.
Several research firms recently weighed in on VNDA. Zacks Investment Research upgraded Vanda Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $17.00 target price for the company in a research note on Tuesday, November 8th. Brean Capital set a $24.00 price target on Vanda Pharmaceuticals and gave the stock a “buy” rating in a research report on Monday, October 10th. Aegis began coverage on Vanda Pharmaceuticals in a research report on Wednesday, November 9th. They set a “buy” rating and a $24.00 price target on the stock. Piper Jaffray Cos. set a $19.00 price target on Vanda Pharmaceuticals and gave the stock a “buy” rating in a research report on Monday, October 24th. Finally, Jefferies Group began coverage on Vanda Pharmaceuticals in a research report on Thursday, October 6th. They set a “buy” rating and a $23.00 price target on the stock. Six equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $21.00.
In other news, insider James E. Flynn sold 547,886 shares of the stock in a transaction dated Monday, September 19th. The stock was sold at an average price of $15.66, for a total value of $8,579,894.76. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider James E. Flynn sold 1,120,461 shares of the stock in a transaction dated Friday, September 23rd. The shares were sold at an average price of $16.56, for a total value of $18,554,834.16. The disclosure for this sale can be found here. 8.45% of the stock is owned by insiders.
Vanda Pharmaceuticals Company Profile
Vanda Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products for the treatment of central nervous system (CNS) disorders. The Company’s product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051.